Effect of Exopolysaccharide produced by Levilactobacillus brevis OR921362 on HEK 293 and HeLa cell lines

The current research involved isolating exopolysaccharide (EPS) producer, Levilactobacillus brevis OR921362 from fermented cucumber using modified MRS media. LB-EPS (exopolysaccharide produced by the isolate) has exhibited antimicrobial activity and dose-response against indicator organisms like P aeroginosa MTCC10307, E coli MTCC452, K pneumoniae MTCC4031, S aureus MTCC3160. The minimum inhibitory concentration analysis of LB-EPS was investigated using Azithromycin as a standard drug. At the highest concentration of 1000µg/ml LB-EPS has exhibited 65%, 86%, 82%, and 81% inhibition rate, whereas the standard drug has displayed 46%, 79%, 64%, and 78% inhibition against indicator organisms P aeroginosa MTCC10307, E coli MTCC452, K pneumoniae MTCC4031, S aureus MTCC3160 respectively. LB-EPS was further studied for cytotoxicity assessment against the HEK 293 and HeLa cell lines. The percentage of decrease in viability with an increase in concentration of LB-EPS was observed, determining 319.87±2.64 µg/ml as the IC50 value. On HeLa cell line LB-EPS at the highest concentration, the percentage of viability and inhibition was observed to be 33.15% and 66.85% respectively with an IC50 value of 63.75±0.927µg/ml. For a comparative study, Cisplatin was used as a standard drug. Statistically, there was a significant difference in the antitumor activity at different LB-EPS and standard drug concentrations with p<0.05.